akcea-angptl3-lrx
Nucleic acidexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2017 (NCT03371355)
Timeline
Indications
Studied for
- Chylomicrons · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Dyslipidemias · Phase 2
- Healthy Volunteers · Phase 1
- Homozygous Familial Hypercholesterolemia · Phase 2
- Hyperlipidemias · Phase 2
- Hyperlipoproteinemias · Phase 2
- Hyperlipoproteinemia Type I · Phase 2
- Hypertriglyceridemia · Phase 2
- Lipodystrophy, Familial Partial · Phase 2
- Lipoproteins · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
Mechanism of action
- Angiopoietin like 3 (ANGPTL3) mRNAANTISENSE INHIBITOR
Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor
- Asialoglycoprotein receptor 1BINDING AGENT
Asialoglycoprotein receptor 1 binding agent
- Angiopoietin-related protein 3INHIBITOR
ANGPTL3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298197 ↗
Also known as
- akcea-angptl3-lrx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04916795 | Phase 1 | Jun 17, 2021 | Pfizer |
| NCT04516291 | Phase 2 | Sep 28, 2020 | Pfizer, TIMI Study Group, Boston, MA |
| NCT04459767 | Phase 1 | Aug 6, 2020 | Pfizer |
| NCT03514420 | Phase 2 | May 30, 2018 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT03455777 | Phase 2 | Apr 12, 2018 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT03360747 | Phase 2 | Dec 21, 2017 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT03371355 | Phase 2 | Dec 18, 2017 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akcea Therapeutics | For profit | 4 | 4 | 1 | 2017 |
| Ionis Pharmaceuticals, Inc. | For profit | 4 | 0 | 1 | 2017 |
| Pfizer | For profit | 3 | 3 | 2 | 2020 |
| TIMI Study Group, Boston, MA | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1